nodes	percent_of_prediction	percent_of_DWPC	metapath
Carfilzomib—Proteasome Inhibitors—Bortezomib—hematologic cancer	0.527	1	CiPCiCtD
Carfilzomib—PSMB5—Bortezomib—hematologic cancer	0.0669	0.237	CbGbCtD
Carfilzomib—PSMB2—Bortezomib—hematologic cancer	0.0669	0.237	CbGbCtD
Carfilzomib—PSMB1—Bortezomib—hematologic cancer	0.0669	0.237	CbGbCtD
Carfilzomib—PSMB8—Bortezomib—hematologic cancer	0.0669	0.237	CbGbCtD
Carfilzomib—ABCB1—hematologic cancer	0.0339	1	CbGaD
Carfilzomib—ABCB1—Lenalidomide—hematologic cancer	0.00214	0.00758	CbGbCtD
Carfilzomib—PSMB10—hematopoietic system—hematologic cancer	0.00191	0.0871	CbGeAlD
Carfilzomib—PSMB10—blood—hematologic cancer	0.00127	0.0577	CbGeAlD
Carfilzomib—ABCB1—Daunorubicin—hematologic cancer	0.00126	0.00444	CbGbCtD
Carfilzomib—ABCB1—Alitretinoin—hematologic cancer	0.00123	0.00435	CbGbCtD
Carfilzomib—PSMB10—lung—hematologic cancer	0.00111	0.0506	CbGeAlD
Carfilzomib—PSMB10—testis—hematologic cancer	0.00105	0.0478	CbGeAlD
Carfilzomib—ABCB1—Imatinib—hematologic cancer	0.000962	0.0034	CbGbCtD
Carfilzomib—PSMB1—hematopoietic system—hematologic cancer	0.000951	0.0434	CbGeAlD
Carfilzomib—PSMB2—hematopoietic system—hematologic cancer	0.000928	0.0423	CbGeAlD
Carfilzomib—ABCB1—Nilotinib—hematologic cancer	0.000875	0.00309	CbGbCtD
Carfilzomib—ABCB1—Vinorelbine—hematologic cancer	0.000867	0.00307	CbGbCtD
Carfilzomib—PSMB8—blood—hematologic cancer	0.000816	0.0372	CbGeAlD
Carfilzomib—PSMB8—bone marrow—hematologic cancer	0.000789	0.036	CbGeAlD
Carfilzomib—ABCB1—Dasatinib—hematologic cancer	0.000773	0.00273	CbGbCtD
Carfilzomib—ABCB1—Mitoxantrone—hematologic cancer	0.000764	0.0027	CbGbCtD
Carfilzomib—PSMB10—lymph node—hematologic cancer	0.000759	0.0346	CbGeAlD
Carfilzomib—PSMB1—gonad—hematologic cancer	0.000723	0.033	CbGeAlD
Carfilzomib—PSMB5—blood—hematologic cancer	0.000721	0.0329	CbGeAlD
Carfilzomib—PSMB8—lung—hematologic cancer	0.000715	0.0326	CbGeAlD
Carfilzomib—PSMB2—gonad—hematologic cancer	0.000705	0.0322	CbGeAlD
Carfilzomib—PSMB5—bone marrow—hematologic cancer	0.000697	0.0318	CbGeAlD
Carfilzomib—ABCB1—Betamethasone—hematologic cancer	0.000681	0.00241	CbGbCtD
Carfilzomib—PSMB8—testis—hematologic cancer	0.000675	0.0308	CbGeAlD
Carfilzomib—ABCB1—Gemcitabine—hematologic cancer	0.000674	0.00239	CbGbCtD
Carfilzomib—ABCB1—Prednisolone—hematologic cancer	0.000671	0.00238	CbGbCtD
Carfilzomib—ABCB1—Prednisone—hematologic cancer	0.000634	0.00224	CbGbCtD
Carfilzomib—PSMB5—lung—hematologic cancer	0.000632	0.0288	CbGeAlD
Carfilzomib—PSMB1—blood—hematologic cancer	0.00063	0.0287	CbGeAlD
Carfilzomib—PSMB2—blood—hematologic cancer	0.000615	0.028	CbGeAlD
Carfilzomib—PSMB1—bone marrow—hematologic cancer	0.00061	0.0278	CbGeAlD
Carfilzomib—ABCB1—Irinotecan—hematologic cancer	0.000601	0.00213	CbGbCtD
Carfilzomib—PSMB5—testis—hematologic cancer	0.000596	0.0272	CbGeAlD
Carfilzomib—PSMB2—bone marrow—hematologic cancer	0.000595	0.0271	CbGeAlD
Carfilzomib—PSMB1—lung—hematologic cancer	0.000552	0.0252	CbGeAlD
Carfilzomib—PSMB2—lung—hematologic cancer	0.000539	0.0246	CbGeAlD
Carfilzomib—ABCB1—Vinblastine—hematologic cancer	0.000534	0.00189	CbGbCtD
Carfilzomib—ABCB1—Vincristine—hematologic cancer	0.000525	0.00186	CbGbCtD
Carfilzomib—PSMB1—testis—hematologic cancer	0.000521	0.0238	CbGeAlD
Carfilzomib—PSMB2—testis—hematologic cancer	0.000508	0.0232	CbGeAlD
Carfilzomib—ABCB1—Cisplatin—hematologic cancer	0.00049	0.00173	CbGbCtD
Carfilzomib—PSMB8—lymph node—hematologic cancer	0.000489	0.0223	CbGeAlD
Carfilzomib—ABCB1—Etoposide—hematologic cancer	0.000481	0.0017	CbGbCtD
Carfilzomib—PSMB5—lymph node—hematologic cancer	0.000432	0.0197	CbGeAlD
Carfilzomib—ABCB1—Dexamethasone—hematologic cancer	0.000396	0.0014	CbGbCtD
Carfilzomib—PSMB1—lymph node—hematologic cancer	0.000378	0.0172	CbGeAlD
Carfilzomib—PSMB2—lymph node—hematologic cancer	0.000368	0.0168	CbGeAlD
Carfilzomib—ABCB1—Doxorubicin—hematologic cancer	0.000328	0.00116	CbGbCtD
Carfilzomib—ABCB1—Methotrexate—hematologic cancer	0.000318	0.00113	CbGbCtD
Carfilzomib—Ritonavir—ABCG2—hematologic cancer	0.00016	0.523	CrCbGaD
Carfilzomib—ABCB1—hematopoietic system—hematologic cancer	0.000142	0.00646	CbGeAlD
Carfilzomib—PSMB8—Ponatinib—Nilotinib—hematologic cancer	0.000141	0.0927	CbGdCrCtD
Carfilzomib—ABCB1—gonad—hematologic cancer	0.000108	0.00491	CbGeAlD
Carfilzomib—PSMB8—Ponatinib—Imatinib—hematologic cancer	0.000107	0.0702	CbGdCrCtD
Carfilzomib—PSMB10—Vinblastine—Vinorelbine—hematologic cancer	0.000103	0.0677	CbGdCrCtD
Carfilzomib—ABCB1—blood—hematologic cancer	9.39e-05	0.00428	CbGeAlD
Carfilzomib—ABCB1—bone marrow—hematologic cancer	9.09e-05	0.00414	CbGeAlD
Carfilzomib—PSMB2—Azacitidine—Pentostatin—hematologic cancer	8.29e-05	0.0546	CbGdCrCtD
Carfilzomib—ABCB1—lung—hematologic cancer	8.23e-05	0.00375	CbGeAlD
Carfilzomib—PSMB10—Vinblastine—Vincristine—hematologic cancer	8.21e-05	0.0542	CbGdCrCtD
Carfilzomib—Lopinavir—ABCB1—hematologic cancer	7.93e-05	0.259	CrCbGaD
Carfilzomib—ABCB1—testis—hematologic cancer	7.77e-05	0.00354	CbGeAlD
Carfilzomib—PSMB8—Podofilox—Teniposide—hematologic cancer	7.65e-05	0.0504	CbGdCrCtD
Carfilzomib—PSMB2—Azacitidine—Clofarabine—hematologic cancer	7.38e-05	0.0487	CbGdCrCtD
Carfilzomib—PSMB2—Azacitidine—Nelarabine—hematologic cancer	6.94e-05	0.0458	CbGdCrCtD
Carfilzomib—Ritonavir—ABCB1—hematologic cancer	6.66e-05	0.218	CrCbGaD
Carfilzomib—ABCB1—lymph node—hematologic cancer	5.63e-05	0.00257	CbGeAlD
Carfilzomib—PSMB2—Azacitidine—Fludarabine—hematologic cancer	5.42e-05	0.0357	CbGdCrCtD
Carfilzomib—PSMB2—Azacitidine—Cytarabine—hematologic cancer	5.12e-05	0.0337	CbGdCrCtD
Carfilzomib—PSMB2—Azacitidine—Gemcitabine—hematologic cancer	5.12e-05	0.0337	CbGdCrCtD
Carfilzomib—PSMB2—Azacitidine—Cladribine—hematologic cancer	4.99e-05	0.0329	CbGdCrCtD
Carfilzomib—PSMB8—Vincristine—Vinorelbine—hematologic cancer	4.87e-05	0.0321	CbGdCrCtD
Carfilzomib—PSMB8—Vinorelbine—Vinblastine—hematologic cancer	4.55e-05	0.03	CbGdCrCtD
Carfilzomib—PSMB8—Vinorelbine—Vincristine—hematologic cancer	4.55e-05	0.03	CbGdCrCtD
Carfilzomib—PSMB8—Podofilox—Etoposide—hematologic cancer	4.55e-05	0.03	CbGdCrCtD
Carfilzomib—PSMB8—Vincristine—Vinblastine—hematologic cancer	3.89e-05	0.0257	CbGdCrCtD
Carfilzomib—PSMB9—Betamethasone—Dexamethasone—hematologic cancer	2.36e-05	0.0156	CbGdCrCtD
Carfilzomib—PSMB9—Dexamethasone—Betamethasone—hematologic cancer	2.36e-05	0.0156	CbGdCrCtD
Carfilzomib—PSMB9—Betamethasone—Triamcinolone—hematologic cancer	2.31e-05	0.0152	CbGdCrCtD
Carfilzomib—PSMB9—Dexamethasone—Triamcinolone—hematologic cancer	2.31e-05	0.0152	CbGdCrCtD
Carfilzomib—PSMB9—Betamethasone—Prednisone—hematologic cancer	2.19e-05	0.0144	CbGdCrCtD
Carfilzomib—PSMB9—Dexamethasone—Prednisone—hematologic cancer	2.19e-05	0.0144	CbGdCrCtD
Carfilzomib—PSMB9—Dexamethasone—Prednisolone—hematologic cancer	2.14e-05	0.0141	CbGdCrCtD
Carfilzomib—PSMB9—Betamethasone—Prednisolone—hematologic cancer	2.14e-05	0.0141	CbGdCrCtD
Carfilzomib—PSMB8—Medrysone—Prednisolone—hematologic cancer	1.67e-05	0.011	CbGdCrCtD
Carfilzomib—Upper respiratory tract infection—Methotrexate—hematologic cancer	1.53e-05	0.000212	CcSEcCtD
Carfilzomib—Body temperature increased—Vincristine—hematologic cancer	1.53e-05	0.000211	CcSEcCtD
Carfilzomib—Dyspnoea—Cisplatin—hematologic cancer	1.52e-05	0.00021	CcSEcCtD
Carfilzomib—Cough—Triamcinolone—hematologic cancer	1.52e-05	0.00021	CcSEcCtD
Carfilzomib—Asthenia—Thalidomide—hematologic cancer	1.51e-05	0.000209	CcSEcCtD
Carfilzomib—Dizziness—Vinorelbine—hematologic cancer	1.51e-05	0.000208	CcSEcCtD
Carfilzomib—Nausea—Lenalidomide—hematologic cancer	1.51e-05	0.000208	CcSEcCtD
Carfilzomib—Hypokalaemia—Doxorubicin—hematologic cancer	1.5e-05	0.000208	CcSEcCtD
Carfilzomib—Hypertension—Triamcinolone—hematologic cancer	1.5e-05	0.000207	CcSEcCtD
Carfilzomib—Anorexia—Etoposide—hematologic cancer	1.49e-05	0.000206	CcSEcCtD
Carfilzomib—Diarrhoea—Thiotepa—hematologic cancer	1.49e-05	0.000206	CcSEcCtD
Carfilzomib—Body temperature increased—Mitoxantrone—hematologic cancer	1.49e-05	0.000205	CcSEcCtD
Carfilzomib—Body temperature increased—Irinotecan—hematologic cancer	1.49e-05	0.000205	CcSEcCtD
Carfilzomib—Aspartate aminotransferase increased—Doxorubicin—hematologic cancer	1.49e-05	0.000205	CcSEcCtD
Carfilzomib—Nausea—Hydroxyurea—hematologic cancer	1.49e-05	0.000205	CcSEcCtD
Carfilzomib—Vomiting—Bortezomib—hematologic cancer	1.49e-05	0.000205	CcSEcCtD
Carfilzomib—Decreased appetite—Cisplatin—hematologic cancer	1.49e-05	0.000205	CcSEcCtD
Carfilzomib—Pneumonia—Methotrexate—hematologic cancer	1.48e-05	0.000204	CcSEcCtD
Carfilzomib—Vomiting—Bleomycin—hematologic cancer	1.48e-05	0.000204	CcSEcCtD
Carfilzomib—Headache—Bortezomib—hematologic cancer	1.46e-05	0.000202	CcSEcCtD
Carfilzomib—Pain—Cisplatin—hematologic cancer	1.46e-05	0.000202	CcSEcCtD
Carfilzomib—Asthenia—Carmustine—hematologic cancer	1.45e-05	0.000201	CcSEcCtD
Carfilzomib—Vomiting—Vinorelbine—hematologic cancer	1.45e-05	0.0002	CcSEcCtD
Carfilzomib—Body temperature increased—Gemcitabine—hematologic cancer	1.45e-05	0.0002	CcSEcCtD
Carfilzomib—Renal failure—Methotrexate—hematologic cancer	1.45e-05	0.0002	CcSEcCtD
Carfilzomib—Neutropenia—Epirubicin—hematologic cancer	1.44e-05	0.000199	CcSEcCtD
Carfilzomib—Diarrhoea—Thalidomide—hematologic cancer	1.44e-05	0.000199	CcSEcCtD
Carfilzomib—Dizziness—Thiotepa—hematologic cancer	1.44e-05	0.000199	CcSEcCtD
Carfilzomib—Asthenia—Alitretinoin—hematologic cancer	1.44e-05	0.000199	CcSEcCtD
Carfilzomib—Upper respiratory tract infection—Epirubicin—hematologic cancer	1.43e-05	0.000198	CcSEcCtD
Carfilzomib—Headache—Vinorelbine—hematologic cancer	1.43e-05	0.000197	CcSEcCtD
Carfilzomib—Asthenia—Ifosfamide—hematologic cancer	1.42e-05	0.000196	CcSEcCtD
Carfilzomib—Infection—Triamcinolone—hematologic cancer	1.41e-05	0.000195	CcSEcCtD
Carfilzomib—Insomnia—Prednisolone—hematologic cancer	1.4e-05	0.000193	CcSEcCtD
Carfilzomib—Dyspnoea—Etoposide—hematologic cancer	1.4e-05	0.000193	CcSEcCtD
Carfilzomib—Dizziness—Thalidomide—hematologic cancer	1.39e-05	0.000193	CcSEcCtD
Carfilzomib—Hyperglycaemia—Epirubicin—hematologic cancer	1.39e-05	0.000192	CcSEcCtD
Carfilzomib—Nausea—Bortezomib—hematologic cancer	1.39e-05	0.000192	CcSEcCtD
Carfilzomib—Asthenia—Vincristine—hematologic cancer	1.39e-05	0.000192	CcSEcCtD
Carfilzomib—Vomiting—Thiotepa—hematologic cancer	1.39e-05	0.000191	CcSEcCtD
Carfilzomib—Diarrhoea—Carmustine—hematologic cancer	1.39e-05	0.000191	CcSEcCtD
Carfilzomib—Pneumonia—Epirubicin—hematologic cancer	1.38e-05	0.000191	CcSEcCtD
Carfilzomib—Nausea—Bleomycin—hematologic cancer	1.38e-05	0.00019	CcSEcCtD
Carfilzomib—Diarrhoea—Alitretinoin—hematologic cancer	1.37e-05	0.00019	CcSEcCtD
Carfilzomib—Headache—Thiotepa—hematologic cancer	1.37e-05	0.000189	CcSEcCtD
Carfilzomib—Hypertension—Dexamethasone—hematologic cancer	1.36e-05	0.000188	CcSEcCtD
Carfilzomib—Hypertension—Betamethasone—hematologic cancer	1.36e-05	0.000188	CcSEcCtD
Carfilzomib—Decreased appetite—Etoposide—hematologic cancer	1.36e-05	0.000188	CcSEcCtD
Carfilzomib—Diarrhoea—Ifosfamide—hematologic cancer	1.36e-05	0.000187	CcSEcCtD
Carfilzomib—Nausea—Vinorelbine—hematologic cancer	1.36e-05	0.000187	CcSEcCtD
Carfilzomib—Renal failure—Epirubicin—hematologic cancer	1.35e-05	0.000187	CcSEcCtD
Carfilzomib—Body temperature increased—Cisplatin—hematologic cancer	1.35e-05	0.000187	CcSEcCtD
Carfilzomib—Asthenia—Irinotecan—hematologic cancer	1.35e-05	0.000187	CcSEcCtD
Carfilzomib—Asthenia—Mitoxantrone—hematologic cancer	1.35e-05	0.000187	CcSEcCtD
Carfilzomib—Fatigue—Etoposide—hematologic cancer	1.35e-05	0.000186	CcSEcCtD
Carfilzomib—Neuropathy peripheral—Epirubicin—hematologic cancer	1.35e-05	0.000186	CcSEcCtD
Carfilzomib—Vomiting—Thalidomide—hematologic cancer	1.34e-05	0.000185	CcSEcCtD
Carfilzomib—Dizziness—Carmustine—hematologic cancer	1.34e-05	0.000185	CcSEcCtD
Carfilzomib—Pain—Etoposide—hematologic cancer	1.34e-05	0.000185	CcSEcCtD
Carfilzomib—Constipation—Etoposide—hematologic cancer	1.34e-05	0.000185	CcSEcCtD
Carfilzomib—PSMB8—Fluorometholone—Betamethasone—hematologic cancer	1.34e-05	0.00881	CbGdCrCtD
Carfilzomib—PSMB8—Fluorometholone—Dexamethasone—hematologic cancer	1.34e-05	0.00881	CbGdCrCtD
Carfilzomib—Neutropenia—Doxorubicin—hematologic cancer	1.34e-05	0.000184	CcSEcCtD
Carfilzomib—Upper respiratory tract infection—Doxorubicin—hematologic cancer	1.33e-05	0.000183	CcSEcCtD
Carfilzomib—Dizziness—Alitretinoin—hematologic cancer	1.33e-05	0.000183	CcSEcCtD
Carfilzomib—Diarrhoea—Vincristine—hematologic cancer	1.32e-05	0.000183	CcSEcCtD
Carfilzomib—Headache—Thalidomide—hematologic cancer	1.32e-05	0.000182	CcSEcCtD
Carfilzomib—Pain—Prednisolone—hematologic cancer	1.32e-05	0.000182	CcSEcCtD
Carfilzomib—Asthenia—Gemcitabine—hematologic cancer	1.32e-05	0.000182	CcSEcCtD
Carfilzomib—Dizziness—Ifosfamide—hematologic cancer	1.31e-05	0.000181	CcSEcCtD
Carfilzomib—PSMB8—Fluorometholone—Triamcinolone—hematologic cancer	1.31e-05	0.0086	CbGdCrCtD
Carfilzomib—Nausea—Thiotepa—hematologic cancer	1.3e-05	0.000179	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Triamcinolone—hematologic cancer	1.29e-05	0.000179	CcSEcCtD
Carfilzomib—Hyperglycaemia—Doxorubicin—hematologic cancer	1.29e-05	0.000178	CcSEcCtD
Carfilzomib—Diarrhoea—Mitoxantrone—hematologic cancer	1.29e-05	0.000178	CcSEcCtD
Carfilzomib—Diarrhoea—Irinotecan—hematologic cancer	1.29e-05	0.000178	CcSEcCtD
Carfilzomib—Vomiting—Carmustine—hematologic cancer	1.29e-05	0.000178	CcSEcCtD
Carfilzomib—Insomnia—Triamcinolone—hematologic cancer	1.28e-05	0.000177	CcSEcCtD
Carfilzomib—Pneumonia—Doxorubicin—hematologic cancer	1.28e-05	0.000177	CcSEcCtD
Carfilzomib—Infection—Betamethasone—hematologic cancer	1.28e-05	0.000177	CcSEcCtD
Carfilzomib—Infection—Dexamethasone—hematologic cancer	1.28e-05	0.000177	CcSEcCtD
Carfilzomib—Dizziness—Vincristine—hematologic cancer	1.28e-05	0.000177	CcSEcCtD
Carfilzomib—Vomiting—Alitretinoin—hematologic cancer	1.28e-05	0.000176	CcSEcCtD
Carfilzomib—Anaemia—Prednisone—hematologic cancer	1.27e-05	0.000176	CcSEcCtD
Carfilzomib—Headache—Carmustine—hematologic cancer	1.27e-05	0.000175	CcSEcCtD
Carfilzomib—Dyspnoea—Triamcinolone—hematologic cancer	1.27e-05	0.000175	CcSEcCtD
Carfilzomib—Thrombocytopenia—Betamethasone—hematologic cancer	1.26e-05	0.000174	CcSEcCtD
Carfilzomib—Thrombocytopenia—Dexamethasone—hematologic cancer	1.26e-05	0.000174	CcSEcCtD
Carfilzomib—Vomiting—Ifosfamide—hematologic cancer	1.26e-05	0.000174	CcSEcCtD
Carfilzomib—Headache—Alitretinoin—hematologic cancer	1.26e-05	0.000174	CcSEcCtD
Carfilzomib—Diarrhoea—Gemcitabine—hematologic cancer	1.25e-05	0.000173	CcSEcCtD
Carfilzomib—Nausea—Thalidomide—hematologic cancer	1.25e-05	0.000173	CcSEcCtD
Carfilzomib—Renal failure—Doxorubicin—hematologic cancer	1.25e-05	0.000173	CcSEcCtD
Carfilzomib—Neuropathy peripheral—Doxorubicin—hematologic cancer	1.25e-05	0.000172	CcSEcCtD
Carfilzomib—Dizziness—Irinotecan—hematologic cancer	1.25e-05	0.000172	CcSEcCtD
Carfilzomib—PSMB8—Fluorometholone—Prednisone—hematologic cancer	1.24e-05	0.00817	CbGdCrCtD
Carfilzomib—Body temperature increased—Etoposide—hematologic cancer	1.24e-05	0.000171	CcSEcCtD
Carfilzomib—Hypoaesthesia—Epirubicin—hematologic cancer	1.23e-05	0.00017	CcSEcCtD
Carfilzomib—Vomiting—Vincristine—hematologic cancer	1.23e-05	0.00017	CcSEcCtD
Carfilzomib—Anorexia—Dexamethasone—hematologic cancer	1.23e-05	0.00017	CcSEcCtD
Carfilzomib—Anorexia—Betamethasone—hematologic cancer	1.23e-05	0.00017	CcSEcCtD
Carfilzomib—Asthenia—Cisplatin—hematologic cancer	1.23e-05	0.000169	CcSEcCtD
Carfilzomib—Cardiac disorder—Methotrexate—hematologic cancer	1.23e-05	0.000169	CcSEcCtD
Carfilzomib—Fatigue—Triamcinolone—hematologic cancer	1.22e-05	0.000169	CcSEcCtD
Carfilzomib—Oedema peripheral—Epirubicin—hematologic cancer	1.22e-05	0.000168	CcSEcCtD
Carfilzomib—Pain—Triamcinolone—hematologic cancer	1.21e-05	0.000168	CcSEcCtD
Carfilzomib—Headache—Vincristine—hematologic cancer	1.21e-05	0.000167	CcSEcCtD
Carfilzomib—PSMB8—Fluorometholone—Prednisolone—hematologic cancer	1.21e-05	0.00797	CbGdCrCtD
Carfilzomib—Nausea—Carmustine—hematologic cancer	1.2e-05	0.000166	CcSEcCtD
Carfilzomib—Vomiting—Irinotecan—hematologic cancer	1.2e-05	0.000165	CcSEcCtD
Carfilzomib—Vomiting—Mitoxantrone—hematologic cancer	1.2e-05	0.000165	CcSEcCtD
Carfilzomib—Nausea—Alitretinoin—hematologic cancer	1.19e-05	0.000165	CcSEcCtD
Carfilzomib—Hypertension—Prednisone—hematologic cancer	1.19e-05	0.000164	CcSEcCtD
Carfilzomib—Chills—Methotrexate—hematologic cancer	1.18e-05	0.000164	CcSEcCtD
Carfilzomib—Headache—Mitoxantrone—hematologic cancer	1.18e-05	0.000163	CcSEcCtD
Carfilzomib—Headache—Irinotecan—hematologic cancer	1.18e-05	0.000163	CcSEcCtD
Carfilzomib—Nausea—Ifosfamide—hematologic cancer	1.18e-05	0.000163	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Dexamethasone—hematologic cancer	1.17e-05	0.000162	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Betamethasone—hematologic cancer	1.17e-05	0.000162	CcSEcCtD
Carfilzomib—Arthralgia—Prednisone—hematologic cancer	1.17e-05	0.000162	CcSEcCtD
Carfilzomib—Diarrhoea—Cisplatin—hematologic cancer	1.17e-05	0.000161	CcSEcCtD
Carfilzomib—Vomiting—Gemcitabine—hematologic cancer	1.17e-05	0.000161	CcSEcCtD
Carfilzomib—Insomnia—Betamethasone—hematologic cancer	1.17e-05	0.000161	CcSEcCtD
Carfilzomib—Insomnia—Dexamethasone—hematologic cancer	1.17e-05	0.000161	CcSEcCtD
Carfilzomib—Headache—Gemcitabine—hematologic cancer	1.15e-05	0.000159	CcSEcCtD
Carfilzomib—Nausea—Vincristine—hematologic cancer	1.15e-05	0.000159	CcSEcCtD
Carfilzomib—Cardiac disorder—Epirubicin—hematologic cancer	1.15e-05	0.000158	CcSEcCtD
Carfilzomib—Hypoaesthesia—Doxorubicin—hematologic cancer	1.14e-05	0.000157	CcSEcCtD
Carfilzomib—Oedema peripheral—Doxorubicin—hematologic cancer	1.13e-05	0.000155	CcSEcCtD
Carfilzomib—Asthenia—Etoposide—hematologic cancer	1.12e-05	0.000155	CcSEcCtD
Carfilzomib—Body temperature increased—Triamcinolone—hematologic cancer	1.12e-05	0.000155	CcSEcCtD
Carfilzomib—Decreased appetite—Dexamethasone—hematologic cancer	1.12e-05	0.000155	CcSEcCtD
Carfilzomib—Decreased appetite—Betamethasone—hematologic cancer	1.12e-05	0.000155	CcSEcCtD
Carfilzomib—Nausea—Mitoxantrone—hematologic cancer	1.12e-05	0.000154	CcSEcCtD
Carfilzomib—Nausea—Irinotecan—hematologic cancer	1.12e-05	0.000154	CcSEcCtD
Carfilzomib—Infection—Prednisone—hematologic cancer	1.12e-05	0.000154	CcSEcCtD
Carfilzomib—Back pain—Methotrexate—hematologic cancer	1.11e-05	0.000153	CcSEcCtD
Carfilzomib—Fatigue—Betamethasone—hematologic cancer	1.11e-05	0.000153	CcSEcCtD
Carfilzomib—Fatigue—Dexamethasone—hematologic cancer	1.11e-05	0.000153	CcSEcCtD
Carfilzomib—Chills—Epirubicin—hematologic cancer	1.11e-05	0.000153	CcSEcCtD
Carfilzomib—Pain—Betamethasone—hematologic cancer	1.1e-05	0.000152	CcSEcCtD
Carfilzomib—Pain—Dexamethasone—hematologic cancer	1.1e-05	0.000152	CcSEcCtD
Carfilzomib—Nausea—Gemcitabine—hematologic cancer	1.09e-05	0.00015	CcSEcCtD
Carfilzomib—Vomiting—Cisplatin—hematologic cancer	1.09e-05	0.00015	CcSEcCtD
Carfilzomib—Diarrhoea—Etoposide—hematologic cancer	1.07e-05	0.000148	CcSEcCtD
Carfilzomib—Anorexia—Prednisone—hematologic cancer	1.07e-05	0.000148	CcSEcCtD
Carfilzomib—Anaemia—Methotrexate—hematologic cancer	1.06e-05	0.000147	CcSEcCtD
Carfilzomib—Cardiac disorder—Doxorubicin—hematologic cancer	1.06e-05	0.000146	CcSEcCtD
Carfilzomib—Back pain—Epirubicin—hematologic cancer	1.04e-05	0.000144	CcSEcCtD
Carfilzomib—Dizziness—Etoposide—hematologic cancer	1.04e-05	0.000143	CcSEcCtD
Carfilzomib—Muscle spasms—Epirubicin—hematologic cancer	1.03e-05	0.000143	CcSEcCtD
Carfilzomib—Leukopenia—Methotrexate—hematologic cancer	1.03e-05	0.000142	CcSEcCtD
Carfilzomib—Chills—Doxorubicin—hematologic cancer	1.03e-05	0.000142	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Prednisone—hematologic cancer	1.02e-05	0.000141	CcSEcCtD
Carfilzomib—Dizziness—Prednisolone—hematologic cancer	1.02e-05	0.000141	CcSEcCtD
Carfilzomib—Asthenia—Triamcinolone—hematologic cancer	1.02e-05	0.000141	CcSEcCtD
Carfilzomib—Body temperature increased—Dexamethasone—hematologic cancer	1.02e-05	0.000141	CcSEcCtD
Carfilzomib—Body temperature increased—Betamethasone—hematologic cancer	1.02e-05	0.000141	CcSEcCtD
Carfilzomib—PSMB8—Diflorasone—Dexamethasone—hematologic cancer	1.02e-05	0.00671	CbGdCrCtD
Carfilzomib—PSMB8—Diflorasone—Betamethasone—hematologic cancer	1.02e-05	0.00671	CbGdCrCtD
Carfilzomib—Nausea—Cisplatin—hematologic cancer	1.02e-05	0.00014	CcSEcCtD
Carfilzomib—Insomnia—Prednisone—hematologic cancer	1.02e-05	0.00014	CcSEcCtD
Carfilzomib—Cough—Methotrexate—hematologic cancer	1e-05	0.000138	CcSEcCtD
Carfilzomib—Vomiting—Etoposide—hematologic cancer	9.96e-06	0.000137	CcSEcCtD
Carfilzomib—Anaemia—Epirubicin—hematologic cancer	9.94e-06	0.000137	CcSEcCtD
Carfilzomib—PSMB8—Diflorasone—Triamcinolone—hematologic cancer	9.94e-06	0.00655	CbGdCrCtD
Carfilzomib—Headache—Etoposide—hematologic cancer	9.81e-06	0.000135	CcSEcCtD
Carfilzomib—Arthralgia—Methotrexate—hematologic cancer	9.79e-06	0.000135	CcSEcCtD
Carfilzomib—Decreased appetite—Prednisone—hematologic cancer	9.76e-06	0.000135	CcSEcCtD
Carfilzomib—Fatigue—Prednisone—hematologic cancer	9.68e-06	0.000134	CcSEcCtD
Carfilzomib—Headache—Prednisolone—hematologic cancer	9.68e-06	0.000134	CcSEcCtD
Carfilzomib—Leukopenia—Epirubicin—hematologic cancer	9.63e-06	0.000133	CcSEcCtD
Carfilzomib—Back pain—Doxorubicin—hematologic cancer	9.63e-06	0.000133	CcSEcCtD
Carfilzomib—Constipation—Prednisone—hematologic cancer	9.6e-06	0.000133	CcSEcCtD
Carfilzomib—Muscle spasms—Doxorubicin—hematologic cancer	9.57e-06	0.000132	CcSEcCtD
Carfilzomib—PSMB8—Diflorasone—Prednisone—hematologic cancer	9.43e-06	0.00622	CbGdCrCtD
Carfilzomib—Dizziness—Triamcinolone—hematologic cancer	9.39e-06	0.00013	CcSEcCtD
Carfilzomib—Cough—Epirubicin—hematologic cancer	9.39e-06	0.00013	CcSEcCtD
Carfilzomib—Infection—Methotrexate—hematologic cancer	9.32e-06	0.000129	CcSEcCtD
Carfilzomib—Nausea—Etoposide—hematologic cancer	9.3e-06	0.000128	CcSEcCtD
Carfilzomib—Hypertension—Epirubicin—hematologic cancer	9.29e-06	0.000128	CcSEcCtD
Carfilzomib—Asthenia—Dexamethasone—hematologic cancer	9.25e-06	0.000128	CcSEcCtD
Carfilzomib—Asthenia—Betamethasone—hematologic cancer	9.25e-06	0.000128	CcSEcCtD
Carfilzomib—PSMB8—Diflorasone—Prednisolone—hematologic cancer	9.21e-06	0.00607	CbGdCrCtD
Carfilzomib—Anaemia—Doxorubicin—hematologic cancer	9.2e-06	0.000127	CcSEcCtD
Carfilzomib—Thrombocytopenia—Methotrexate—hematologic cancer	9.18e-06	0.000127	CcSEcCtD
Carfilzomib—Nausea—Prednisolone—hematologic cancer	9.17e-06	0.000127	CcSEcCtD
Carfilzomib—Arthralgia—Epirubicin—hematologic cancer	9.16e-06	0.000126	CcSEcCtD
Carfilzomib—Vomiting—Triamcinolone—hematologic cancer	9.03e-06	0.000125	CcSEcCtD
Carfilzomib—Anorexia—Methotrexate—hematologic cancer	8.94e-06	0.000123	CcSEcCtD
Carfilzomib—Leukopenia—Doxorubicin—hematologic cancer	8.91e-06	0.000123	CcSEcCtD
Carfilzomib—Headache—Triamcinolone—hematologic cancer	8.9e-06	0.000123	CcSEcCtD
Carfilzomib—Body temperature increased—Prednisone—hematologic cancer	8.87e-06	0.000123	CcSEcCtD
Carfilzomib—Diarrhoea—Dexamethasone—hematologic cancer	8.82e-06	0.000122	CcSEcCtD
Carfilzomib—Diarrhoea—Betamethasone—hematologic cancer	8.82e-06	0.000122	CcSEcCtD
Carfilzomib—Infection—Epirubicin—hematologic cancer	8.72e-06	0.00012	CcSEcCtD
Carfilzomib—Cough—Doxorubicin—hematologic cancer	8.68e-06	0.00012	CcSEcCtD
Carfilzomib—Thrombocytopenia—Epirubicin—hematologic cancer	8.6e-06	0.000119	CcSEcCtD
Carfilzomib—Hypertension—Doxorubicin—hematologic cancer	8.59e-06	0.000119	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Methotrexate—hematologic cancer	8.55e-06	0.000118	CcSEcCtD
Carfilzomib—Dizziness—Dexamethasone—hematologic cancer	8.52e-06	0.000118	CcSEcCtD
Carfilzomib—Dizziness—Betamethasone—hematologic cancer	8.52e-06	0.000118	CcSEcCtD
Carfilzomib—Insomnia—Methotrexate—hematologic cancer	8.48e-06	0.000117	CcSEcCtD
Carfilzomib—Arthralgia—Doxorubicin—hematologic cancer	8.47e-06	0.000117	CcSEcCtD
Carfilzomib—Nausea—Triamcinolone—hematologic cancer	8.44e-06	0.000116	CcSEcCtD
Carfilzomib—Anorexia—Epirubicin—hematologic cancer	8.37e-06	0.000116	CcSEcCtD
Carfilzomib—Dyspnoea—Methotrexate—hematologic cancer	8.36e-06	0.000115	CcSEcCtD
Carfilzomib—Vomiting—Betamethasone—hematologic cancer	8.19e-06	0.000113	CcSEcCtD
Carfilzomib—Vomiting—Dexamethasone—hematologic cancer	8.19e-06	0.000113	CcSEcCtD
Carfilzomib—Decreased appetite—Methotrexate—hematologic cancer	8.15e-06	0.000113	CcSEcCtD
Carfilzomib—Fatigue—Methotrexate—hematologic cancer	8.09e-06	0.000112	CcSEcCtD
Carfilzomib—Headache—Dexamethasone—hematologic cancer	8.07e-06	0.000111	CcSEcCtD
Carfilzomib—Headache—Betamethasone—hematologic cancer	8.07e-06	0.000111	CcSEcCtD
Carfilzomib—Infection—Doxorubicin—hematologic cancer	8.07e-06	0.000111	CcSEcCtD
Carfilzomib—Asthenia—Prednisone—hematologic cancer	8.05e-06	0.000111	CcSEcCtD
Carfilzomib—Pain—Methotrexate—hematologic cancer	8.02e-06	0.000111	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Epirubicin—hematologic cancer	8e-06	0.00011	CcSEcCtD
Carfilzomib—Thrombocytopenia—Doxorubicin—hematologic cancer	7.95e-06	0.00011	CcSEcCtD
Carfilzomib—Insomnia—Epirubicin—hematologic cancer	7.94e-06	0.00011	CcSEcCtD
Carfilzomib—Dyspnoea—Epirubicin—hematologic cancer	7.83e-06	0.000108	CcSEcCtD
Carfilzomib—Anorexia—Doxorubicin—hematologic cancer	7.74e-06	0.000107	CcSEcCtD
Carfilzomib—Diarrhoea—Prednisone—hematologic cancer	7.68e-06	0.000106	CcSEcCtD
Carfilzomib—Nausea—Dexamethasone—hematologic cancer	7.66e-06	0.000106	CcSEcCtD
Carfilzomib—Nausea—Betamethasone—hematologic cancer	7.66e-06	0.000106	CcSEcCtD
Carfilzomib—Decreased appetite—Epirubicin—hematologic cancer	7.63e-06	0.000105	CcSEcCtD
Carfilzomib—Fatigue—Epirubicin—hematologic cancer	7.57e-06	0.000104	CcSEcCtD
Carfilzomib—Pain—Epirubicin—hematologic cancer	7.51e-06	0.000104	CcSEcCtD
Carfilzomib—Constipation—Epirubicin—hematologic cancer	7.51e-06	0.000104	CcSEcCtD
Carfilzomib—Dizziness—Prednisone—hematologic cancer	7.42e-06	0.000102	CcSEcCtD
Carfilzomib—Body temperature increased—Methotrexate—hematologic cancer	7.42e-06	0.000102	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Doxorubicin—hematologic cancer	7.4e-06	0.000102	CcSEcCtD
Carfilzomib—Insomnia—Doxorubicin—hematologic cancer	7.35e-06	0.000101	CcSEcCtD
Carfilzomib—Dyspnoea—Doxorubicin—hematologic cancer	7.24e-06	0.0001	CcSEcCtD
Carfilzomib—Vomiting—Prednisone—hematologic cancer	7.14e-06	9.85e-05	CcSEcCtD
Carfilzomib—Decreased appetite—Doxorubicin—hematologic cancer	7.06e-06	9.75e-05	CcSEcCtD
Carfilzomib—Headache—Prednisone—hematologic cancer	7.03e-06	9.71e-05	CcSEcCtD
Carfilzomib—Fatigue—Doxorubicin—hematologic cancer	7e-06	9.67e-05	CcSEcCtD
Carfilzomib—Pain—Doxorubicin—hematologic cancer	6.95e-06	9.59e-05	CcSEcCtD
Carfilzomib—Constipation—Doxorubicin—hematologic cancer	6.95e-06	9.59e-05	CcSEcCtD
Carfilzomib—Body temperature increased—Epirubicin—hematologic cancer	6.94e-06	9.58e-05	CcSEcCtD
Carfilzomib—Asthenia—Methotrexate—hematologic cancer	6.73e-06	9.29e-05	CcSEcCtD
Carfilzomib—Nausea—Prednisone—hematologic cancer	6.67e-06	9.2e-05	CcSEcCtD
Carfilzomib—Body temperature increased—Doxorubicin—hematologic cancer	6.42e-06	8.87e-05	CcSEcCtD
Carfilzomib—Diarrhoea—Methotrexate—hematologic cancer	6.42e-06	8.86e-05	CcSEcCtD
Carfilzomib—Asthenia—Epirubicin—hematologic cancer	6.3e-06	8.7e-05	CcSEcCtD
Carfilzomib—Dizziness—Methotrexate—hematologic cancer	6.2e-06	8.56e-05	CcSEcCtD
Carfilzomib—Diarrhoea—Epirubicin—hematologic cancer	6.01e-06	8.29e-05	CcSEcCtD
Carfilzomib—Vomiting—Methotrexate—hematologic cancer	5.96e-06	8.23e-05	CcSEcCtD
Carfilzomib—Headache—Methotrexate—hematologic cancer	5.88e-06	8.11e-05	CcSEcCtD
Carfilzomib—Asthenia—Doxorubicin—hematologic cancer	5.83e-06	8.05e-05	CcSEcCtD
Carfilzomib—Dizziness—Epirubicin—hematologic cancer	5.81e-06	8.01e-05	CcSEcCtD
Carfilzomib—Vomiting—Epirubicin—hematologic cancer	5.58e-06	7.71e-05	CcSEcCtD
Carfilzomib—Nausea—Methotrexate—hematologic cancer	5.57e-06	7.69e-05	CcSEcCtD
Carfilzomib—Diarrhoea—Doxorubicin—hematologic cancer	5.56e-06	7.67e-05	CcSEcCtD
Carfilzomib—Headache—Epirubicin—hematologic cancer	5.5e-06	7.59e-05	CcSEcCtD
Carfilzomib—PSMB8—Betamethasone—Dexamethasone—hematologic cancer	5.46e-06	0.0036	CbGdCrCtD
Carfilzomib—PSMB8—Dexamethasone—Betamethasone—hematologic cancer	5.46e-06	0.0036	CbGdCrCtD
Carfilzomib—Dizziness—Doxorubicin—hematologic cancer	5.37e-06	7.42e-05	CcSEcCtD
Carfilzomib—PSMB8—Dexamethasone—Triamcinolone—hematologic cancer	5.33e-06	0.00351	CbGdCrCtD
Carfilzomib—PSMB8—Betamethasone—Triamcinolone—hematologic cancer	5.33e-06	0.00351	CbGdCrCtD
Carfilzomib—Nausea—Epirubicin—hematologic cancer	5.21e-06	7.2e-05	CcSEcCtD
Carfilzomib—Vomiting—Doxorubicin—hematologic cancer	5.16e-06	7.13e-05	CcSEcCtD
Carfilzomib—Headache—Doxorubicin—hematologic cancer	5.09e-06	7.03e-05	CcSEcCtD
Carfilzomib—PSMB8—Dexamethasone—Prednisone—hematologic cancer	5.06e-06	0.00334	CbGdCrCtD
Carfilzomib—PSMB8—Betamethasone—Prednisone—hematologic cancer	5.06e-06	0.00334	CbGdCrCtD
Carfilzomib—PSMB8—Betamethasone—Prednisolone—hematologic cancer	4.94e-06	0.00326	CbGdCrCtD
Carfilzomib—PSMB8—Dexamethasone—Prednisolone—hematologic cancer	4.94e-06	0.00326	CbGdCrCtD
Carfilzomib—Nausea—Doxorubicin—hematologic cancer	4.82e-06	6.66e-05	CcSEcCtD
Carfilzomib—PSMB2—Signaling Pathways—PIK3R1—hematologic cancer	9.83e-07	1.64e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—FGF2—hematologic cancer	9.83e-07	1.64e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—EP300—hematologic cancer	9.82e-07	1.63e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—NUP98—hematologic cancer	9.81e-07	1.63e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—PIK3R1—hematologic cancer	9.7e-07	1.61e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Disease—HRAS—hematologic cancer	9.65e-07	1.61e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Disease—HRAS—hematologic cancer	9.6e-07	1.6e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—SRC—hematologic cancer	9.6e-07	1.6e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—MAPK3—hematologic cancer	9.57e-07	1.59e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—MAPK3—hematologic cancer	9.57e-07	1.59e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—MAPK3—hematologic cancer	9.57e-07	1.59e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—JAK2—hematologic cancer	9.56e-07	1.59e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—JAK2—hematologic cancer	9.56e-07	1.59e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—JAK2—hematologic cancer	9.56e-07	1.59e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—SRC—hematologic cancer	9.55e-07	1.59e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—NCOA3—hematologic cancer	9.52e-07	1.59e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—ADCY7—hematologic cancer	9.52e-07	1.59e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—NUP214—hematologic cancer	9.46e-07	1.57e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—MAPK3—hematologic cancer	9.44e-07	1.57e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—JAK2—hematologic cancer	9.42e-07	1.57e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Metabolism—PTEN—hematologic cancer	9.38e-07	1.56e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Metabolism—PTEN—hematologic cancer	9.38e-07	1.56e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Metabolism—PTEN—hematologic cancer	9.38e-07	1.56e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—VEGFA—hematologic cancer	9.35e-07	1.56e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—MDM2—hematologic cancer	9.33e-07	1.55e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—MDM2—hematologic cancer	9.33e-07	1.55e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—MDM2—hematologic cancer	9.33e-07	1.55e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—KRAS—hematologic cancer	9.32e-07	1.55e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—KRAS—hematologic cancer	9.32e-07	1.55e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—KRAS—hematologic cancer	9.32e-07	1.55e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—MYC—hematologic cancer	9.31e-07	1.55e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—MYC—hematologic cancer	9.31e-07	1.55e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—MYC—hematologic cancer	9.31e-07	1.55e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—VEGFA—hematologic cancer	9.3e-07	1.55e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—TGFB1—hematologic cancer	9.29e-07	1.55e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—TGFB1—hematologic cancer	9.29e-07	1.55e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—TGFB1—hematologic cancer	9.29e-07	1.55e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—MTR—hematologic cancer	9.27e-07	1.54e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—ABCG2—hematologic cancer	9.27e-07	1.54e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—STAT3—hematologic cancer	9.26e-07	1.54e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Metabolism—PTEN—hematologic cancer	9.25e-07	1.54e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—NRAS—hematologic cancer	9.23e-07	1.54e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Disease—IL6—hematologic cancer	9.23e-07	1.54e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Immune System—AKT1—hematologic cancer	9.23e-07	1.54e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—STAT3—hematologic cancer	9.21e-07	1.53e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—MDM2—hematologic cancer	9.2e-07	1.53e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—NRAS—hematologic cancer	9.19e-07	1.53e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Disease—IL6—hematologic cancer	9.19e-07	1.53e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—KRAS—hematologic cancer	9.18e-07	1.53e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Immune System—AKT1—hematologic cancer	9.18e-07	1.53e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—MYC—hematologic cancer	9.18e-07	1.53e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Gene Expression—AKT1—hematologic cancer	9.17e-07	1.53e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—TGFB1—hematologic cancer	9.16e-07	1.52e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Gene Expression—AKT1—hematologic cancer	9.13e-07	1.52e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—ENO2—hematologic cancer	9.09e-07	1.51e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—PIK3CB—hematologic cancer	9.08e-07	1.51e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—PIK3CB—hematologic cancer	9.08e-07	1.51e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—PIK3CB—hematologic cancer	9.08e-07	1.51e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—MTOR—hematologic cancer	9.08e-07	1.51e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—MTOR—hematologic cancer	9.08e-07	1.51e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—MTOR—hematologic cancer	9.08e-07	1.51e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—PIK3CB—hematologic cancer	8.95e-07	1.49e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—MTOR—hematologic cancer	8.95e-07	1.49e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Metabolism—EP300—hematologic cancer	8.95e-07	1.49e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Metabolism—EP300—hematologic cancer	8.95e-07	1.49e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Metabolism—EP300—hematologic cancer	8.95e-07	1.49e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—MAPK3—hematologic cancer	8.84e-07	1.47e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Metabolism—EP300—hematologic cancer	8.82e-07	1.47e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—GSTT1—hematologic cancer	8.81e-07	1.47e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—MAPK3—hematologic cancer	8.8e-07	1.46e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Metabolism—PIK3CA—hematologic cancer	8.73e-07	1.45e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Metabolism—PIK3CA—hematologic cancer	8.69e-07	1.45e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—SDC1—hematologic cancer	8.61e-07	1.43e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—MYC—hematologic cancer	8.6e-07	1.43e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—KRAS—hematologic cancer	8.6e-07	1.43e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—KRAS—hematologic cancer	8.6e-07	1.43e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—KRAS—hematologic cancer	8.6e-07	1.43e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—TGFB1—hematologic cancer	8.58e-07	1.43e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—MYC—hematologic cancer	8.56e-07	1.42e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—PIK3CA—hematologic cancer	8.56e-07	1.42e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—PIK3CA—hematologic cancer	8.56e-07	1.42e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—PIK3CA—hematologic cancer	8.56e-07	1.42e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—hematologic cancer	8.55e-07	1.42e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—TGFB1—hematologic cancer	8.54e-07	1.42e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—CDKN1B—hematologic cancer	8.52e-07	1.42e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—CDKN1B—hematologic cancer	8.52e-07	1.42e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—CDKN1B—hematologic cancer	8.52e-07	1.42e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Disease—AKT1—hematologic cancer	8.52e-07	1.42e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—KRAS—hematologic cancer	8.48e-07	1.41e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Disease—AKT1—hematologic cancer	8.48e-07	1.41e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—PIK3CA—hematologic cancer	8.44e-07	1.4e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—CDKN1B—hematologic cancer	8.4e-07	1.4e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—CASP3—hematologic cancer	8.35e-07	1.39e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—CASP3—hematologic cancer	8.35e-07	1.39e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—CASP3—hematologic cancer	8.35e-07	1.39e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—IL2—hematologic cancer	8.34e-07	1.39e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—IL2—hematologic cancer	8.34e-07	1.39e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—IL2—hematologic cancer	8.34e-07	1.39e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Transmembrane transport of small molecules—CREBBP—hematologic cancer	8.25e-07	1.37e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—CASP3—hematologic cancer	8.23e-07	1.37e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—IL2—hematologic cancer	8.22e-07	1.37e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—CCND1—hematologic cancer	8.13e-07	1.35e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—CCND1—hematologic cancer	8.13e-07	1.35e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—CCND1—hematologic cancer	8.13e-07	1.35e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—JUN—hematologic cancer	8.11e-07	1.35e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—JUN—hematologic cancer	8.11e-07	1.35e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—JUN—hematologic cancer	8.11e-07	1.35e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—CCND1—hematologic cancer	8.01e-07	1.33e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—JUN—hematologic cancer	8e-07	1.33e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—KRAS—hematologic cancer	7.95e-07	1.32e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—HRAS—hematologic cancer	7.92e-07	1.32e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—HRAS—hematologic cancer	7.92e-07	1.32e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—HRAS—hematologic cancer	7.92e-07	1.32e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—KRAS—hematologic cancer	7.91e-07	1.32e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—PIK3CA—hematologic cancer	7.9e-07	1.32e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—PIK3CA—hematologic cancer	7.9e-07	1.32e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—PIK3CA—hematologic cancer	7.9e-07	1.32e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—CDKN1A—hematologic cancer	7.86e-07	1.31e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—CDKN1A—hematologic cancer	7.86e-07	1.31e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—CDKN1A—hematologic cancer	7.86e-07	1.31e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—PTEN—hematologic cancer	7.84e-07	1.31e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—PTEN—hematologic cancer	7.84e-07	1.31e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—PTEN—hematologic cancer	7.84e-07	1.31e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—HRAS—hematologic cancer	7.81e-07	1.3e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—PIK3CA—hematologic cancer	7.79e-07	1.3e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—CDKN1A—hematologic cancer	7.75e-07	1.29e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—PTEN—hematologic cancer	7.73e-07	1.29e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Transmembrane transport of small molecules—ALB—hematologic cancer	7.72e-07	1.29e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—MAPK8—hematologic cancer	7.67e-07	1.28e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—MAPK8—hematologic cancer	7.67e-07	1.28e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—MAPK8—hematologic cancer	7.67e-07	1.28e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—IL6—hematologic cancer	7.58e-07	1.26e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—IL6—hematologic cancer	7.58e-07	1.26e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—IL6—hematologic cancer	7.58e-07	1.26e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—MAPK8—hematologic cancer	7.57e-07	1.26e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—EP300—hematologic cancer	7.48e-07	1.24e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—EP300—hematologic cancer	7.48e-07	1.24e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—EP300—hematologic cancer	7.48e-07	1.24e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—IL6—hematologic cancer	7.47e-07	1.24e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—EP300—hematologic cancer	7.38e-07	1.23e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—CD44—hematologic cancer	7.32e-07	1.22e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—NQO1—hematologic cancer	7.32e-07	1.22e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—HRAS—hematologic cancer	7.31e-07	1.22e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—HRAS—hematologic cancer	7.31e-07	1.22e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—HRAS—hematologic cancer	7.31e-07	1.22e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—PIK3CA—hematologic cancer	7.3e-07	1.22e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—SRC—hematologic cancer	7.27e-07	1.21e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—SRC—hematologic cancer	7.27e-07	1.21e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—SRC—hematologic cancer	7.27e-07	1.21e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—PIK3CA—hematologic cancer	7.27e-07	1.21e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—HRAS—hematologic cancer	7.21e-07	1.2e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—SRC—hematologic cancer	7.17e-07	1.19e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Metabolism—AKT1—hematologic cancer	7.13e-07	1.19e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Metabolism—AKT1—hematologic cancer	7.1e-07	1.18e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—VEGFA—hematologic cancer	7.08e-07	1.18e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—VEGFA—hematologic cancer	7.08e-07	1.18e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—VEGFA—hematologic cancer	7.08e-07	1.18e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—TP53—hematologic cancer	7.06e-07	1.18e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—TP53—hematologic cancer	7.03e-07	1.17e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—STAT3—hematologic cancer	7.02e-07	1.17e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—STAT3—hematologic cancer	7.02e-07	1.17e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—STAT3—hematologic cancer	7.02e-07	1.17e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—NRAS—hematologic cancer	7e-07	1.16e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—NRAS—hematologic cancer	7e-07	1.16e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—NRAS—hematologic cancer	7e-07	1.16e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—IL6—hematologic cancer	7e-07	1.16e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—IL6—hematologic cancer	7e-07	1.16e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—IL6—hematologic cancer	7e-07	1.16e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—AKT1—hematologic cancer	6.99e-07	1.16e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—AKT1—hematologic cancer	6.99e-07	1.16e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—AKT1—hematologic cancer	6.99e-07	1.16e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—VEGFA—hematologic cancer	6.98e-07	1.16e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Gene Expression—AKT1—hematologic cancer	6.95e-07	1.16e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Gene Expression—AKT1—hematologic cancer	6.95e-07	1.16e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Gene Expression—AKT1—hematologic cancer	6.95e-07	1.16e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—CYCS—hematologic cancer	6.93e-07	1.15e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—STAT3—hematologic cancer	6.92e-07	1.15e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—NRAS—hematologic cancer	6.9e-07	1.15e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—IL6—hematologic cancer	6.9e-07	1.15e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—AKT1—hematologic cancer	6.89e-07	1.15e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—HSP90AA1—hematologic cancer	6.89e-07	1.15e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Gene Expression—AKT1—hematologic cancer	6.85e-07	1.14e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—HRAS—hematologic cancer	6.76e-07	1.12e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—HRAS—hematologic cancer	6.72e-07	1.12e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—MAPK3—hematologic cancer	6.7e-07	1.12e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—MAPK3—hematologic cancer	6.7e-07	1.12e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—MAPK3—hematologic cancer	6.7e-07	1.12e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Metabolism—PIK3CA—hematologic cancer	6.62e-07	1.1e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Metabolism—PIK3CA—hematologic cancer	6.62e-07	1.1e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Metabolism—PIK3CA—hematologic cancer	6.62e-07	1.1e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—MAPK3—hematologic cancer	6.61e-07	1.1e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Metabolism—PIK3CA—hematologic cancer	6.52e-07	1.09e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—MYC—hematologic cancer	6.52e-07	1.08e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—MYC—hematologic cancer	6.52e-07	1.08e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—MYC—hematologic cancer	6.52e-07	1.08e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—TGFB1—hematologic cancer	6.5e-07	1.08e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—TGFB1—hematologic cancer	6.5e-07	1.08e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—TGFB1—hematologic cancer	6.5e-07	1.08e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—IL6—hematologic cancer	6.47e-07	1.08e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—AKT1—hematologic cancer	6.46e-07	1.07e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—AKT1—hematologic cancer	6.46e-07	1.07e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—AKT1—hematologic cancer	6.46e-07	1.07e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—IL6—hematologic cancer	6.43e-07	1.07e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—MYC—hematologic cancer	6.43e-07	1.07e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—TGFB1—hematologic cancer	6.41e-07	1.07e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—AKT1—hematologic cancer	6.36e-07	1.06e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—GSTP1—hematologic cancer	6.11e-07	1.02e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—KRAS—hematologic cancer	6.02e-07	1e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—KRAS—hematologic cancer	6.02e-07	1e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—KRAS—hematologic cancer	6.02e-07	1e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—AKT1—hematologic cancer	5.96e-07	9.93e-06	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—KRAS—hematologic cancer	5.94e-07	9.88e-06	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—AKT1—hematologic cancer	5.94e-07	9.88e-06	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—GSTM1—hematologic cancer	5.61e-07	9.34e-06	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—NCOR1—hematologic cancer	5.61e-07	9.34e-06	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—PIK3CA—hematologic cancer	5.53e-07	9.21e-06	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—PIK3CA—hematologic cancer	5.53e-07	9.21e-06	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—PIK3CA—hematologic cancer	5.53e-07	9.21e-06	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—PIK3CA—hematologic cancer	5.46e-07	9.08e-06	CbGpPWpGaD
Carfilzomib—PSMB1—Metabolism—AKT1—hematologic cancer	5.41e-07	9e-06	CbGpPWpGaD
Carfilzomib—PSMB5—Metabolism—AKT1—hematologic cancer	5.41e-07	9e-06	CbGpPWpGaD
Carfilzomib—PSMB2—Metabolism—AKT1—hematologic cancer	5.41e-07	9e-06	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—TP53—hematologic cancer	5.35e-07	8.91e-06	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—TP53—hematologic cancer	5.35e-07	8.91e-06	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—TP53—hematologic cancer	5.35e-07	8.91e-06	CbGpPWpGaD
Carfilzomib—PSMB8—Metabolism—AKT1—hematologic cancer	5.33e-07	8.87e-06	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—TP53—hematologic cancer	5.28e-07	8.78e-06	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—HRAS—hematologic cancer	5.12e-07	8.52e-06	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—HRAS—hematologic cancer	5.12e-07	8.52e-06	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—HRAS—hematologic cancer	5.12e-07	8.52e-06	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—HRAS—hematologic cancer	5.05e-07	8.4e-06	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—MTHFR—hematologic cancer	4.96e-07	8.26e-06	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—IL6—hematologic cancer	4.9e-07	8.15e-06	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—IL6—hematologic cancer	4.9e-07	8.15e-06	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—IL6—hematologic cancer	4.9e-07	8.15e-06	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—IL6—hematologic cancer	4.83e-07	8.04e-06	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—AKT1—hematologic cancer	4.52e-07	7.52e-06	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—AKT1—hematologic cancer	4.52e-07	7.52e-06	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—AKT1—hematologic cancer	4.52e-07	7.52e-06	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—AKT1—hematologic cancer	4.46e-07	7.42e-06	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—PIK3CG—hematologic cancer	4.17e-07	6.94e-06	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—CREBBP—hematologic cancer	3.86e-07	6.43e-06	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—PIK3CD—hematologic cancer	3.66e-07	6.1e-06	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—ALB—hematologic cancer	3.62e-07	6.02e-06	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—PIK3R1—hematologic cancer	3.46e-07	5.76e-06	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—PIK3CB—hematologic cancer	3.19e-07	5.32e-06	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—PTEN—hematologic cancer	2.76e-07	4.59e-06	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—EP300—hematologic cancer	2.63e-07	4.38e-06	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—PIK3CA—hematologic cancer	1.95e-07	3.24e-06	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—AKT1—hematologic cancer	1.59e-07	2.65e-06	CbGpPWpGaD
